Journal
THERAPEUTIC ADVANCES IN HEMATOLOGY
Volume 8, Issue 3, Pages 107-118Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040620716680333
Keywords
Budd-Chiari syndrome; essential thrombocythemia; JAK2; myeloproliferative neoplasm; polycythemia vera; portal vein thrombosis; primary myelofibrosis; splanchnic vein thrombosis
Categories
Ask authors/readers for more resources
Myeloproliferative neoplasms (MPNs) are the most common underlying prothrombotic disorder found in patients with splanchnic vein thrombosis (SVT). Clinical risk factors for MPN-associated SVTs include younger age, female sex, concomitant hypercoagulable disorders, and the JAK2 V617F mutation. These risk factors are distinct from those associated with arterial or deep venous thrombosis (DVT) in MPN patients, suggesting disparate disease mechanisms. The pathophysiology of SVT is thought to derive from local interactions between activated blood cells and the unique splanchnic endothelial environment. Other mutations commonly found in MPNs, including CALR and MPL, are rare in MPN-associated SVT. The purpose of this article is to review the clinical and molecular risk factors for MPN-associated SVT, with particular focus on the possible mechanisms of SVT formation in MPN patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available